The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Filippo Sprianoa, Luca Aresub, Luciano Cascionea c, Giorgia Risia, Alberto J. Arribasa c, Sara Napolia, Nicole Forster-Grossd, Felix Bachmannd, Marc Frederick Engelhardtd, Heidi A. Laned, Francesco Bertonia e
- aInstitute of Oncology Research, Faculty of Biomedical Sciences, USI Bellinzona, Switzerland
- bDepartment of Veterinary Science, University of Turin Grugliasco, Turin, Italy
- cSIB Swiss Institute of Bioinformatics Lausanne, Switzerland
- dBasilea Pharmaceutica International Ltd Allschwill, Switzerland
- eOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale Bellinzona, Switzerland
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
anti-lymphoma activity, which was mainly cytotoxic with potent and rapid apoptosis induction. Median IC50 was around 10 nM in both ABC and GCB-DLBCL. Half of the cell lines tested showed an induction of apoptosis already in the first 24 h of treatment, the other half in the first 48 h. EB1 showed expression in DLBCL clinical specimens, opening the possibility for a cohort of patients that could potentially benefit from treatment with lisavanbulin. These data show the basis for further preclinical and clinical evaluation of lisavanbulin in the lymphoma field.
TL;DRAvanbulin showed a potent in vitro anti-lymphoma activity, which was mainly cytotoxic with potent and rapid apoptosis induction induction, and the basis for further preclinical and clinical evaluation of lisavanbulin in the lymphoma field is shown. (Semantic Scholar)